McKesson Corporation (MCK) is the largest distributor of pharmaceuticals and medical-surgical supplies in the United States, playing a critical role in the biopharmaceutical supply chain. The company operates through three core business segments: North American Pharmaceutical, Oncology and Multispecialty (providing specialized distribution and practice management via the U.S. Oncology Network), and Prescription Technology Solutions (offering technology and administrative solutions like CoverMyMeds for biopharma and pharmacy partners).

McKesson commands a powerful oligopolistic moat alongside Cencora and Cardinal Health, with the three major distributors jointly controlling ~90% of the U.S. pharmaceutical distribution market. This extreme scale creates formidable barriers to entry rooted in nationwide logistics infrastructure, tight customer integration with major retail chains, hospitals, and health systems, and significant bargaining power with pharmaceutical manufacturers. McKesson has aggressively deepened its high-margin moat in specialty pharma and oncology by building the U.S. Oncology Network, which provides specialized drug logistics, clinical trial access, and practice management to thousands of community oncologists.

• 08/06/2026: CFRA downgraded McKesson to Hold from Buy with a USD 945.00 target price. While acknowledging strong operating fundamentals and low tariff exposure, CFRA noted balanced valuation following multi-year outperformance.
• 08/05/2026: McKesson reported strong Q1 FY 2027 results, exceeding EPS consensus driven by broad-based prescription sales growth and expanding specialty oncology volumes.
• 06/10/2026: Barclays adjusted its price target on MCK to USD 925.00 (from USD 1,050.00) while maintaining an Overweight rating.
• 06/2025: McKesson acquired a ~70% controlling stake in Community Oncology Revitalization Enterprise (CORE) Ventures for $2.49 Billion in cash, partnering with Florida Cancer Specialists & Research Institute to expand its U.S. Oncology Network footprint.
• 04/2025: McKesson acquired an 80% controlling stake in PRISM Vision (retina and ophthalmology practice management platform) for $850 Million, broadening its specialty healthcare service offerings.
• Ongoing Strategic Realignment: McKesson is proceeding with the tax-free separation of its Medical-Surgical business (branded as "Wellverse"), supported by an Apollo Global 13% minority investment and $2.25 Billion in credit facilities. Completion is expected in 2H 2027, streamlining MCK into a pure-play pharmaceutical distribution and biopharma/oncology growth vehicle following its complete exit from European operations in January 2026.

• Supplier Concentration: McKesson's top 10 drug suppliers accounted for 72% of total purchase volume in FY 2025, creating operational dependency on major biopharma manufacturers.
• Regulatory & Pricing Disruption: Potential legislative developments targeting drug pricing (e.g. Inflation Reduction Act IRA drug negotiation expansions) or unfavorable changes in generic drug deflation dynamics could compress distribution spreads.
• Separation Execution Risk: Potential execution friction or cost dissynergies related to the spin-off of the Medical-Surgical (Wellverse) segment targeted for 2H 2027.